What are the known side effects of Elafibranor to be aware of?

Elafibranor (Elafibranor) is an agonist targeting PPAR-α/δ receptor. It is intended to treat metabolic and inflammatory liver diseases such as non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). As a new drug under research, irafibratenol has shown good efficacy in clinical trials, but it is also accompanied by some side effects that need attention. Understanding these possible adverse reactions can help patients better prevent and manage risks during medication.

One of the most common side effects of elafibratenol is gastrointestinal discomfort, mainly manifested as nausea, diarrhea, bloating, or indigestion. This type of reaction usually occurs in the early stages of medication and is tolerated by most patients. However, if symptoms persist or worsen, you need to communicate with your doctor in time. Similar to other drugs that affect metabolism, this gastrointestinal reaction may be related to the drug's regulation of bile acid metabolism and lipid metabolism.

A slight increase in creatine kinase (CK) or muscle discomfort has been observed in some clinical studies, suggesting that irafibratenol may have a certain impact on muscle metabolism. This situation requires more attention when combined with statin lipid-lowering drugs, because both may affect muscle enzyme levels. It is recommended that patients who experience obvious muscle soreness, weakness and other symptoms while taking the drug should promptly conduct muscle enzyme testing and evaluate the safety of the drug.

Ilafibratenol may also cause mild liver function abnormalities, manifested by elevated transaminases (such asALT, AST). Such reactions are common with drugs used to treat liver disease but need to be distinguished from underlying liver disease activity. Doctors usually monitor liver function regularly during treatment. If liver enzymes continue to rise or symptoms such as jaundice occur, the medication may need to be suspended or the dose adjusted.

Although the current clinical data of irafibratenol have not shown obvious serious adverse events, as a drug in the late clinical trial stage, its long-term safety still needs further observation. During use, it is recommended that patients follow medical advice and regularly review blood lipids, liver function, electrolytes and other indicators to ensure the safety of treatment. In short, irafibratenol is generally well tolerated, but it is necessary to remain vigilant for gastrointestinal discomfort, elevated liver enzymes and muscle symptoms to achieve early detection and early intervention.

Reference materials:https://www.drugs.com